Kadmon eyes $15.5K pricetag and August debut for new transplant rejection med Rezurock

Kadmon eyes $15.5K pricetag and August debut for new transplant rejection med Rezurock. 

To see the mission through, the company has primed its sales team, started talks with payers and rolled out an access program dubbed Kadmon Assist, chief commercial officer Haya Taitel said.

On the access side, Kadmon has already started hashing things out with payers and formulary decision-makers, Taitel said. The company has also set up a “hub services” platform called Kadmon Assist, which will offer reimbursement assistance and savings programs to patients. The program will also provide nurse practitioners on-call for patient education and counseling, she said.

fkansteiner Mon, 07/19/2021 – 09:40

Read the source article at Pharma News
2021-07-19 14:40:50